pharma consultancy Archives - DelveInsight

pharma consultancy

transthyretin amyloidosis
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set...

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Gene...


Default Blog Image
Horizon Discovery declines Abcam’s USD 367 million takeover bid

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing...


transthyretin amyloidosis
Notizia

FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitryp...


transthyretin amyloidosis
Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistan...

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After th...


Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.
Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty pro...


Default Blog Image
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs

Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed ...


Default Blog Image
Hepatic Encephalopathy- Lack of active pipeline products

Hepatic encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain. People with long-st...


BioGen
Business Cocktail

Merck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commerc...


Default Blog Image
Hyperuricemia – Uric acid disorder, a gateway to other diseases

Hyperuricemia is a pathological condition occurring due to excess of uric acid in blood (serum uric acid level > 7.0 mg/dL in adult men and > 5.7 mg/dL in adult women). Hyperuricemia occurs ...


BioGen
Business Cocktail

M&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & bloo...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.